Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis.

Glassberg MK, Wijsenbeek MS, Gilberg F, Petzinger U, Kirchgaessler KU, Albera C.

Eur Respir J. 2019 Jun 4. pii: 1900399. doi: 10.1183/13993003.00399-2019. [Epub ahead of print] No abstract available.

PMID:
31164431
2.

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.

Nathan SD, Costabel U, Albera C, Behr J, Wuyts WA, Kirchgaessler KU, Stauffer JL, Morgenthien E, Chou W, Limb SL, Noble PW.

Respir Med. 2019 Jul;153:44-51. doi: 10.1016/j.rmed.2019.04.016. Epub 2019 Apr 24.

3.

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.

Costabel U, Albera C, Glassberg MK, Lancaster LH, Wuyts WA, Petzinger U, Gilberg F, Kirchgaessler KU, Noble PW.

Respir Res. 2019 Mar 12;20(1):55. doi: 10.1186/s12931-019-1021-2.

4.

The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone.

Harari S, Caminati A, Confalonieri M, Poletti V, Vancheri C, Pesci A, Rogliani P, Luppi F, Agostini C, Rottoli P, Sanduzzi Zamparelli A, Sebastiani A, Della Porta R, Salton F, Messore B, Tomassetti S, Rosso R, Biffi A, Puxeddu E, Cerri S, Cinetto F, Refini RM, Bocchino M, Di Michele L, Specchia C, Albera C; ILDINET (Interstitial Lung Diseases Italian Network).

Clin Respir J. 2019 Mar;13(3):166-173. doi: 10.1111/crj.12999.

PMID:
30675755
5.

Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier.

Cristallini C, Barbani N, Ventrelli L, Summa C, Filippi S, Capelôa T, Vitale E, Albera C, Messore B, Giachino C.

Mater Sci Eng C Mater Biol Appl. 2019 Feb 1;95:19-28. doi: 10.1016/j.msec.2018.10.064. Epub 2018 Oct 18.

PMID:
30573241
6.

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.

Cottin V, Koschel D, Günther A, Albera C, Azuma A, Sköld CM, Tomassetti S, Hormel P, Stauffer JL, Strombom I, Kirchgaessler KU, Maher TM.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00084-2018. doi: 10.1183/23120541.00084-2018. eCollection 2018 Oct.

7.

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials.

Nathan SD, Lancaster LH, Albera C, Glassberg MK, Swigris JJ, Gilberg F, Kirchgaessler KU, Limb SL, Petzinger U, Noble PW.

BMJ Open Respir Res. 2018 Aug 2;5(1):e000323. doi: 10.1136/bmjresp-2018-000323. eCollection 2018.

8.

Human renal angiomyolipoma cells of male and female origin can migrate and are influenced by microenvironmental factors.

Bertolini F, Casarotti G, Righi L, Bollito E, Albera C, Racca SA, Colangelo D, Mognetti B.

PLoS One. 2018 Jun 19;13(6):e0199371. doi: 10.1371/journal.pone.0199371. eCollection 2018.

9.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U.

Eur Respir Rev. 2017 Dec 6;26(146). pii: 170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Review.

10.

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).

Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, Noble PW.

Respiration. 2017;94(5):408-415. doi: 10.1159/000479976. Epub 2017 Sep 13.

11.

N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open-Authors' reply.

Behr J, Crestani B, Wells A, Kirchgaessler K, Albera C.

Lancet Respir Med. 2017 Jan;5(1):e3. doi: 10.1016/S2213-2600(16)30418-0. No abstract available.

PMID:
28000597
12.

Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA.

Bousquet J, Bewick M, Cano A, Eklund P, Fico G, Goswami N, Guldemond NA, Henderson D, Hinkema MJ, Liotta G, Mair A, Molloy W, Monaco A, Monsonis-Paya I, Nizinska A, Papadopoulos H, Pavlickova A, Pecorelli S, Prados-Torres A, Roller-Wirnsberger RE, Somekh D, Vera-Muñoz C, Visser F, Farrell J, Malva J, Andersen Ranberg K, Camuzat T, Carriazo AM, Crooks G, Gutter Z, Iaccarino G, Manuel de Keenoy E, Moda G, Rodriguez-Mañas L, Vontetsianos T, Abreu C, Alonso J, Alonso-Bouzon C, Ankri J, Arredondo MT, Avolio F, Bedbrook A, Białoszewski AZ, Blain H, Bourret R, Cabrera-Umpierrez MF, Catala A, O'Caoimh R, Cesari M, Chavannes NH, Correia-da-Sousa J, Dedeu T, Ferrando M, Ferri M, Fokkens WJ, Garcia-Lizana F, Guérin O, Hellings PW, Haahtela T, Illario M, Inzerilli MC, Lodrup Carlsen KC, Kardas P, Keil T, Maggio M, Mendez-Zorrilla A, Menditto E, Mercier J, Michel JP, Murray R, Nogues M, O'Byrne-Maguire I, Pappa D, Parent AS, Pastorino M, Robalo-Cordeiro C, Samolinski B, Siciliano P, Teixeira AM, Tsartara SI, Valiulis A, Vandenplas O, Vasankari T, Vellas B, Vollenbroek-Hutten M, Wickman M, Yorgancioglu A, Zuberbier T, Barbagallo M, Canonica GW, Klimek L, Maggi S, Aberer W, Akdis C, Adcock IM, Agache I, Albera C, Alonso-Trujillo F, Angel Guarcia M, Annesi-Maesano I, Apostolo J, Arshad SH, Attalin V, Avignon A, Bachert C, Baroni I, Bel E, Benson M, Bescos C, Blasi F, Barbara C, Bergmann KC, Bernard PL, Bonini S, Bousquet PJ, Branchini B, Brightling CE, Bruguière V, Bunu C, Bush A, Caimmi DP, Calderon MA, Canovas G, Cardona V, Carlsen KH, Cesario A, Chkhartishvili E, Chiron R, Chivato T, Chung KF, d'Angelantonio M, De Carlo G, Cholley D, Chorin F, Combe B, Compas B, Costa DJ, Costa E, Coste O, Coupet AL, Crepaldi G, Custovic A, Dahl R, Dahlen SE, Demoly P, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Du Toit G, Dubakiene R, Dupeyron A, Emuzyte R, Fiocchi A, Wagner A, Fletcher M, Fonseca J, Fougère B, Gamkrelidze A, Garces G, Garcia-Aymeric J, Garcia-Zapirain B, Gemicioğlu B, Gouder C, Hellquist-Dahl B, Hermosilla-Gimeno I, Héve D, Holland C, Humbert M, Hyland M, Johnston SL, Just J, Jutel M, Kaidashev IP, Khaitov M, Kalayci O, Kalyoncu AF, Keijser W, Kerstjens H, Knezović J, Kowalski M, Koppelman GH, Kotska T, Kovac M, Kull I, Kuna P, Kvedariene V, Lepore V, MacNee W, Maggio M, Magnan A, Majer I, Manning P, Marcucci M, Marti T, Masoli M, Melen E, Miculinic N, Mihaltan F, Milenkovic B, Millot-Keurinck J, Mlinarić H, Momas I, Montefort S, Morais-Almeida M, Moreno-Casbas T, Mösges R, Mullol J, Nadif R, Nalin M, Navarro-Pardo E, Nekam K, Ninot G, Paccard D, Pais S, Palummeri E, Panzner P, Papadopoulos NK, Papanikolaou C, Passalacqua G, Pastor E, Perrot M, Plavec D, Popov TA, Postma DS, Price D, Raffort N, Reuzeau JC, Robine JM, Rodenas F, Robusto F, Roche N, Romano A, Romano V, Rosado-Pinto J, Roubille F, Ruiz F, Ryan D, Salcedo T, Schmid-Grendelmeier P, Schulz H, Schunemann HJ, Serrano E, Sheikh A, Shields M, Siafakas N, Scichilone N, Siciliano P, Skrindo I, Smit HA, Sourdet S, Sousa-Costa E, Spranger O, Sooronbaev T, Sruk V, Sterk PJ, Todo-Bom A, Touchon J, Tramontano D, Triggiani M, Tsartara SI, Valero AL, Valovirta E, van Ganse E, van Hage M, van den Berge M, Vandenplas O, Ventura MT, Vergara I, Vezzani G, Vidal D, Viegi G, Wagemann M, Whalley B, Wickman M, Wilson N, Yiallouros PK, Žagar M, Zaidi A, Zidarn M, Hoogerwerf EJ, Usero J, Zuffada R, Senn A, de Oliveira-Alves B.

J Nutr Health Aging. 2017;21(1):92-104. doi: 10.1007/s12603-016-0803-1.

13.

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19. Erratum in: Lancet Respir Med. 2017 Jan;5(1):e7.

PMID:
27876247
14.

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.

Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ.

Eur Respir J. 2016 Sep;48(3):843-51. doi: 10.1183/13993003.01966-2015. Epub 2016 Jul 28.

15.

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.

Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina E.

J Rheumatol. 2016 Sep;43(9):1672-9. doi: 10.3899/jrheum.151322. Epub 2016 Jul 1.

16.

Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.

Behr J, Bendstrup E, Crestani B, Günther A, Olschewski H, Sköld CM, Wells A, Wuyts W, Koschel D, Kreuter M, Wallaert B, Lin CY, Beck J, Albera C.

Lancet Respir Med. 2016 Jun;4(6):445-53. doi: 10.1016/S2213-2600(16)30044-3. Epub 2016 May 5.

PMID:
27161257
17.

[Preliminary results and future perspectives of the Piedmont Adult Congenital Heart Disease Registry].

Marzullo R, Bordese R, Bassignana A, Ferraro G, Dall'Orto G, Ferrarotti L, Libertucci D, Rissone L, Amoroso G, Actis Dato G, Albera C, Bergamasco L, Agnoletti G.

G Ital Cardiol (Rome). 2016 Mar;17(3):225-33. doi: 10.1714/2190.23668. Italian.

PMID:
27029881
18.

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU.

Thorax. 2016 May;71(5):429-35. doi: 10.1136/thoraxjnl-2015-207011. Epub 2016 Mar 11.

19.

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.

Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

BMJ Open Respir Res. 2016 Jan 12;3(1):e000105. doi: 10.1136/bmjresp-2015-000105. eCollection 2016.

20.

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.

Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr.

Eur Respir J. 2016 Jan;47(1):243-53. doi: 10.1183/13993003.00026-2015. Epub 2015 Dec 2.

21.

Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.

Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, Luppi F, Saltini C, Agostini C, Bargagli E, Sebastiani A, Sanduzzi A, Giunta V, Della Porta R, Bandelli GP, Puglisi S, Tomassetti S, Biffi A, Cerri S, Mari A, Cinetto F, Tirelli F, Farinelli G, Bocchino M, Specchia C, Confalonieri M.

Respir Med. 2015 Jul;109(7):904-13. doi: 10.1016/j.rmed.2015.04.010. Epub 2015 Apr 25.

22.

Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.

Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr.

Respir Med. 2015 Jul;109(7):914-22. doi: 10.1016/j.rmed.2015.04.008. Epub 2015 Apr 24.

23.

Circulating biomarkers in pulmonary arterial hypertension: update and future direction.

Pezzuto B, Badagliacca R, Poscia R, Ghio S, D'Alto M, Vitulo P, Mulè M, Albera C, Volterrani M, Fedele F, Vizza CD.

J Heart Lung Transplant. 2015 Mar;34(3):282-305. doi: 10.1016/j.healun.2014.12.005. Epub 2014 Dec 23. Review.

PMID:
25682555
24.

Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.

Loeh B, Drakopanagiotakis F, Bandelli GP, von der Beck D, Tello S, Cordani E, Rizza E, Barrocu L, Markart P, Seeger W, Guenther A, Albera C.

Am J Respir Crit Care Med. 2015 Jan 1;191(1):110-3. doi: 10.1164/rccm.201406-1106LE. No abstract available.

PMID:
25551350
25.

Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.

Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, Sahn SA, Valeyre D, du Bois RM.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):198-205.

PMID:
25363219
26.

'Real-life' information on pulmonary arterial hypertension: the iPHnet Project.

Poscia R, Ghio S, D'Alto M, Vitulo P, Mulè M, Albera C, Parisi F, Badagliacca R, Fedele F, Vizza CD.

Curr Med Res Opin. 2014 Dec;30(12):2409-14. doi: 10.1185/03007995.2014.960514. Epub 2014 Sep 24.

PMID:
25180610
27.

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.

Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, Shigemitsu H, Barney JB, Culver DA, Hamzeh NY, Wijsenbeek MS, Albera C, Huizar I, Agarwal P, Brodmerkel C, Watt R, Barnathan ES.

Eur Respir J. 2014 Nov;44(5):1296-307. doi: 10.1183/09031936.00000914. Epub 2014 Jul 17.

28.

Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis.

Righi L, Cavallo MC, Gatti G, Monica V, Rapa I, Busso S, Albera C, Volante M, Scagliotti GV, Papotti M.

Am J Clin Pathol. 2014 Jun;141(6):816-27. doi: 10.1309/AJCP0F6WYBXGVDHX.

PMID:
24838326
29.

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.

Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, du Bois RM.

Respirology. 2014 Jul;19(5):740-7. doi: 10.1111/resp.12297. Epub 2014 May 18.

30.

Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report.

Roggero S, Vullo S, Volpe G, Piga A, Albera C.

J Thromb Thrombolysis. 2015 Jan;39(1):139-43. doi: 10.1007/s11239-014-1073-6.

PMID:
24788071
31.

All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.

King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):825-31. doi: 10.1164/rccm.201311-1951OC.

32.

Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning.

Capobianco M, Piccoli G, Neve Vigotti F, Scapoli P, Deagostini MC, Albera C, Roccatello D, Bertolotto A.

Mult Scler. 2014 Jun;20(7):889-91. doi: 10.1177/1352458513519839. Epub 2014 Jan 20.

33.

6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.

du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr.

Eur Respir J. 2014 May;43(5):1421-9. doi: 10.1183/09031936.00131813. Epub 2013 Dec 5.

34.

Where do we stand with IPF treatment?

Albera C, Ferrero C, Rindone E, Zanotto S, Rizza E.

Respir Res. 2013;14 Suppl 1:S7. doi: 10.1186/1465-9921-14-S1-S7. Epub 2013 Apr 16.

35.

Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics.

Costabel U, Albera C, Behr J, Cottin V, Guenther A, Richeldi L.

Respir Res. 2013;14 Suppl 1:S1. doi: 10.1186/1465-9921-14-S1-S1. Epub 2013 Apr 16. No abstract available.

36.

Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU.

Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9. doi: 10.1164/rccm.201105-0840OC. Epub 2011 Sep 22.

37.

Challenges in idiopathic pulmonary fibrosis trials: the point on end-points.

Albera C.

Eur Respir Rev. 2011 Sep 1;20(121):195-200. doi: 10.1183/09059180.00001711. Review.

38.

Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr.

Am J Respir Crit Care Med. 2011 Aug 15;184(4):459-66. doi: 10.1164/rccm.201011-1790OC.

39.

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group.

Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13.

PMID:
21571362
40.

Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr.

Am J Respir Crit Care Med. 2011 May 1;183(9):1231-7. doi: 10.1164/rccm.201007-1179OC. Epub 2010 Dec 3.

41.

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.

King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM; INSPIRE Study Group.

Lancet. 2009 Jul 18;374(9685):222-8. doi: 10.1016/S0140-6736(09)60551-1. Epub 2009 Jun 29.

PMID:
19570573
42.

Three-dimensional demonstration of systemic blood supply to normal left basal segments.

Borasio P, Cardinale L, Lausi R, Albera C, Ardissone E.

JBR-BTR. 2008 Jan-Feb;91(1):24. No abstract available.

43.

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.

Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Müller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES; Sarcoidosis Investigators.

Am J Respir Crit Care Med. 2006 Oct 1;174(7):795-802. Epub 2006 Jul 13.

PMID:
16840744
44.

Repopulation of human pulmonary epithelium by bone marrow cells: a potential means to promote repair.

Albera C, Polak JM, Janes S, Griffiths MJ, Alison MR, Wright NA, Navaratnarasah S, Poulsom R, Jeffery R, Fisher C, Burke M, Bishop AE.

Tissue Eng. 2005 Jul-Aug;11(7-8):1115-21.

PMID:
16144447
45.

First report of the Italian register for diffuse infiltrative lung disorders (RIPID).

Agostini C, Albera C, Bariffi F, De Palma M, Harari S, Lusuardi M, Pesci A, Poletti V, Richeldi L, Rizzato G, Rossi A, Schiavina M, Semenzato G, Tinelli C; Registro Italiano Pneumopatie Infiltrative Diffuse.

Monaldi Arch Chest Dis. 2001 Aug;56(4):364-8.

PMID:
11770220
46.

Tachykinin activation of human monocytes from patients with interstitial lung disease, healthy smokers or healthy volunteers.

Brunelleschi S, Nicali R, Lavagno L, Viano I, Pozzi E, Gagliardi L, Ghio P, Albera C.

Neuropeptides. 2000 Feb;34(1):45-50.

47.

Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.

Garay G, Dupont J, Dragosky M, Nucifora E, Cacchione R, Schnidrig P, Fernández J, Abel-Alzueta, Riveros D, Noviello V, Bèguelin R, Campestri R, Albera C, Nicastro M, Triguboff E.

Leuk Lymphoma. 1997 Aug;26(5-6):595-602.

PMID:
9389366
48.

Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85).

Chacon R, Romero Acuña L, Blajman C, Galvez C, Bruno M, Romero A, Chiessa G, Bader M, Schwan R, Albera C, Santarelli MT, Sousa Martínez F, Nadal J, Viniegra M.

Br J Cancer. 1997;76(4):545-50.

49.

Eosinophils in eosinophilic pneumonia.

Albera C, Ghio P.

Eur Respir J. 1996 Dec;9(12):2437-9. No abstract available.

50.

Tachykinin activation of human alveolar macrophages in tobacco smoke and sarcoidosis: a phenotypical and functional study.

Brunelleschi S, Guidotto S, Viano I, Fantozzi R, Pozzi E, Ghio P, Albera C.

Neuropeptides. 1996 Oct;30(5):456-64.

Supplemental Content

Loading ...
Support Center